Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Carlo Giovanni Traverso
Massachusetts Institute of Technology, Department: Miscellaneous
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vivtex
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Traverso is the co-founder of Vivtex, a company that utilizes a gastrointestinal tract organ robotic interface system (GI-ORIS) to screen organs and facilitate development of new oral therapeutics. Vivtex is in the process of licensing gastrointestinal interfacing technology from MIT.
The research grant will support the development of a high-throughput robot-compatible gastrointestinal interface system to facilitate identification of excipients for oral therapeutics and novel interactors of the entero-endocrine system.
The Partners Committee on Outside Activities (COA) Financial Interest Review Panel evaluated Dr. Traverso’s financial interest in Vivtex in connection with this grant. The Committee determined that research to support continued development of a gastrointestinal interface system was relevant to Vivtex’s business aims. The Committee further determined that, since the company is still in the early stage of formation, research results under this grant could affect the company’s business orientation and research direction. The Committee concluded that the financial interest was related to the research and, given its nature and magnitude, the financial interest could directly and significantly affect the design, conduct, or reporting of this research project. Therefore, the financial interest creates a conflict of interest with this grant under the PHS regulations. The Committee further determined that the conflict of interest can be managed with the implementation of management measures.
A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation
Project Narrative This proposal aims to develop an in vitro model of the gastrointestinal tract with all of the native cellular components found in a large mammal and interface with high-throughput robotics for the development of novel treatments. Specifically, it will contribute to the improvement in management of multiple diseases by providing drug formulations which can be readily absorbed orally including the absorption macromolecules.
Filed on February 26, 2019.
Tell us what you know about Carlo Giovanni Traverso's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.